At the news
? BULLISHIMPACT 4/10 PRESS-RELEASE filed Jul 20, 2026 at 17:00 ET
Telix Pharmaceuticals announced the first patient dosed in its Phase 3 LUTEON1 trial evaluating TLX250-Tx, a CAIX-targeted radiopharmaceutical therapy, in relapsed or recurrent clear cell renal cell carcinoma (ccRCC). This is a positive clinical milestone, but the event is procedural without financial data or near-term catalysts, and the company's stock has historically not reacted strongly to similar announcements.
- First patient dosed in the Phase 3 LUTEON1 trial of TLX250-Tx for relapsed or recurrent ccRCC.
- LUTEON1 is the first Phase 3 study of a CAIX-targeted radiopharmaceutical therapy in ccRCC.
- Telix has a commercial imaging franchise (Illuccix, Gozellix) and multiple late-stage therapeutic candidates, including TLX250-Tx.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access